Indian Pharma Market grows 12.1% in May 2026, sixth straight double-digit month
Synopsis
India's pharmaceutical market has now strung together six straight months of double-digit growth — the longest such run in over two years. With chronic therapies at a series-high 14.6%, nine of ten key segments in double digits, and all three growth levers (volume, price, new launches) firing together, the IPM's May 2026 data is the strongest structural signal the sector has produced in recent memory.
Key Takeaways
The Indian Pharmaceutical Market (IPM) grew 12.1 per cent year-on-year in May 2026 , its sixth consecutive month of double-digit expansion.
Indian pharma companies (83% of IPM) grew 11.9 per cent ; multinational companies grew 13.3 per cent .
Chronic therapies hit a series-high 14.6 per cent growth, reaching 40.6 per cent share of the market.
VMN therapy led all segments at 15.6 per cent ; Cilnidipine-Telmisartan in the cardiac segment grew 28 per cent .
Nine of 10 key therapy segments recorded double-digit growth in May, up from six in March.
MAT growth improved to 10.7 per cent , supported by volume ( 3.2% ), price ( 4.5% ), and new introductions ( 3% ).
The Indian Pharmaceutical Market (IPM) recorded 12.1 per cent year-on-year growth in May 2026, marking its sixth consecutive month of double-digit expansion — the most sustained high-growth streak in over two years, according to a report released on Wednesday, 17 June 2026. The data signals a broad-based recovery across therapy segments, volume, and pricing levers simultaneously.
Domestic and Multinational Companies Both Gain
According to the Equirus Securities report, Indian pharmaceutical companies — which account for 83 per cent of the IPM — posted growth of 11.9 per cent in May. Multinational companies outpaced domestic peers, registering 13.3 per cent growth during the same period.
On a moving annual total (MAT) basis, IPM growth improved to 10.7 per cent in May 2026, underpinned by a well-balanced mix: volume growth of over 3.2 per cent, price growth of over 4.5 per cent, and new product introductions contributing over 3 per cent. The report noted that all three levers improved simultaneously — a relatively rare occurrence that points to structural market strength rather than a single-factor surge.
Chronic Therapies Hit Series-High Growth
Chronic therapies reached a series-high growth of 14.6 per cent in May, with their share of the overall market rising to 40.6 per cent. The cardiac segment led at over 14.7 per cent, followed closely by anti-diabetics at over 14.5 per cent.
Within anti-diabetics, Mounjaro (GLP-1) continued to be a primary growth driver, followed by the Dapagliflozin-Metformin-Sitagliptin combination, according to the report. In the cardiac segment, Cilnidipine-Telmisartan recorded the highest growth at 28 per cent, followed by Sacubitril-Valsartan.
Acute Therapies Also Touch Series-High
Acute therapies touched a series-high growth of 8.3 per cent, reflecting a recovery that complements the chronic segment's momentum. Vitamins, Minerals, and Nutrients (VMN) led all therapy segments at 15.6 per cent growth, while respiratory therapies rebounded to 10.9 per cent.
Notably, nine of the 10 key therapy segments recorded double-digit growth in May, compared with just six in March — a significant broadening of the growth base. Anti-infectives remained the sole segment below double-digit growth at 8.1 per cent, though this represented a recovery from earlier lows.
What This Means for the Sector
The simultaneous strength across chronic and acute therapies, volume, price, and new launches suggests the IPM's current growth cycle is more durable than previous single-driver rallies. This comes amid rising healthcare awareness, an ageing population, and growing penetration of branded generics in Tier 2 and Tier 3 cities. If the trend holds through the June quarter, full-year MAT growth could comfortably exceed prior-year levels, setting a stronger baseline for pharmaceutical earnings across listed companies.
Point of View
Price, and new launches all moved up together, which has not been the norm in recent IPM cycles where price hikes alone inflated headline numbers. The chronic segment's rise to 40.6% market share reflects a structural demographic shift: India's disease burden is increasingly non-communicable, and the market is repricing accordingly. The GLP-1 wave — led by Mounjaro — is still in its early innings domestically, and if penetration deepens, anti-diabetic growth could sustain well above trend. The one watch point: anti-infectives lagging at 8.1% may reflect antibiotic stewardship gains, but could also signal softer acute infection incidence post-season. The next two months will clarify which it is.
NationPress
11 Aug 2026
Frequently Asked Questions
What is the Indian Pharmaceutical Market (IPM) growth rate for May 2026?
The IPM recorded 12.1 per cent year-on-year growth in May 2026, according to an Equirus Securities report. This marks the sixth consecutive month of double-digit expansion and the most sustained high-growth run in over two years.
Which therapy segments led IPM growth in May 2026?
Vitamins, Minerals, and Nutrients (VMN) led all segments at 15.6 per cent growth, followed by cardiac therapies at over 14.7 per cent and anti-diabetics at over 14.5 per cent. Chronic therapies as a whole hit a series-high of 14.6 per cent.
How did Indian and multinational pharma companies compare in May 2026?
Indian pharmaceutical companies, which account for 83 per cent of the IPM, grew 11.9 per cent in May. Multinational companies outpaced them at 13.3 per cent growth during the same period.
What drove growth within the anti-diabetic segment?
Within anti-diabetics, Mounjaro (GLP-1) was the primary growth driver, followed by the Dapagliflozin-Metformin-Sitagliptin combination, according to the Equirus Securities report.
How broad-based was IPM growth in May 2026?
Growth was notably broad-based, with nine of the ten key therapy segments recording double-digit growth in May — up from just six segments in March. Anti-infectives were the only segment below double digits, at 8.1 per cent.
